Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
Active, not recruiting · NCT04268706 · Registry updated 2023-04-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) | Hemic and Lymphatic Diseases, Hodgkin Lymphoma, Adult, Hodgkins lymphoma, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2023-04-05 | NCT04268706 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tessa Therapeutics | 3 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Hospital of Philadelphia | Philadelphia | United States | 434 |
| City of Hope Comprehensive Cancer Center | Duarte | United States | 263 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Sarah Cannon Research Institute | Nashville | United States | 119 |
| University of Chicago Medical Center | Chicago | United States | 152 |